洪欢,吴军,阿力比亚提·艾尼

• 1:新疆医科大学附属肿瘤医院乳腺头颈外科

摘要(Abstract)：

目的评价乳腺癌新辅助化疗(neoadjuvant chemotherapy,NCT)的疗效,分析各种临床病理因素对疗效的影响。方法收集290例采用紫杉类或者蒽环类为主的新辅助化疗方案治疗的乳腺癌患者的临床病理资料。采用Miller-Payne病理学方法评价疗效。运用χ~2检验分析临床病理特征与疗效的关系,将有关因素行二元Logistic回归分析。结果单因素分析显示,淋巴结阴性、无钙化、化疗周期≥6个、化疗后Ki-67表达下降和非Luminal型的患者治疗有效率及病理完全缓解(pathological complete response,pCR)率均较高(均P<0.05)。患者治疗有效率在NCT治疗前Ki-67表达水平方面比较,差异具有统计学意义(P<0.05)。pCR率在NCT前Ki-67表达水平方面比较,差异无统计学意义(P=0.222)。多因素分析显示,淋巴结状态、分子分型、钙化、化疗周期和Ki-67变化均是新辅助化疗疗效的独立影响因素(均P<0.05)。淋巴结状态、分子分型和化疗周期≥6个者pCR率高(均P<0.05),是新辅助化疗获得pCR的独立影响因素。结论淋巴结状态和分子分型可作为乳腺癌新辅助化疗获得pCR的有效预测指标。新辅助化疗达到6个周期的患者有较高的pCR。

关键词(KeyWords)： 乳腺肿瘤;新辅助化疗;治疗结果

Abstract:

Keywords:

基金项目(Foundation): 新疆维吾尔自治区自然科学基金(2017D01C408)

作者(Author): 洪欢,吴军,阿力比亚提·艾尼

DOI: 10.13267/j.cnki.syzlzz.2020.01.008

参考文献(References)：

• [1] Gianni L,Eiermann W,Semiglazov V,et al.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH):follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet Oncol,2014,15(6):640-647.
• [2] Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Arch Pathol Lab Med,2010,21(4):336-337.
• [3] Cheang MC,Chia SK,Voduc D,et al.Ki67 index,HER2 status,and prognosis of patients with luminal B breast cancer[J].J Natl Cancer I,2009,101(10):736-750.
• [4] Ogston KN,Miller ID,Payne S,et al.A new histological gradingsystem to assess response of breast cancers to primary chemotherapy:prognostic significance and survival[J].Breast,2003,12(5):320-327.
• [5] 孙冰,宋三泰,江泽飞,等.乳腺癌新辅助化疗病理完全缓解的影响因素分析[J].中华肿瘤杂志,2013,35(1):38-42.
• [6] 周晶,李洪义,汤奉琼,等.乳腺浸润性导管癌X线钙化征象与分子亚型相关性分析[J].医学影像学杂志,2019,29(1):145-149.
• [7] Li JN,Xu J,Wang J,et al.Correlation between mammograghic findings and clinical/pathologic features in women with small invasive breast carcinomas[J].Asian Pac J Cancer P,2014,15(24):10643-10646.
• [8] 肖宇,李惠,雷玉涛,等.乳腺癌新辅助化疗疗效及ER/PR,HER2,Ki67,CyclinA2的化疗预测作用[J].中国微创外科杂志,2011,11(2):163-167.
• [9] Steger GG,Galid A,Gnant M,et al.Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer:results of ABCSG-14[J].J Clin Oncol,2007,25(15):2012-2018.
• [10] Shi Y,Li Q,Li R,et al.Correlation of biomarker expression and therapeutic efficiency in locally advanced breast cancer after neoadjuvant chemotherapy[J].J Modern Oncol,2016,24(1):59-63.
• [11] Lin QI,Liu Y,Chen H,et al.Survivin,Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer[J].Mol Clinical Oncol,2013,1(5):839-844.
• [12] Zhang GC,Qian XK,Guo ZB,et al.Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients[J].Med Oncol,2012,29(5):3222-3231.
• [13] Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes:Dealing with the diversity of breast cancer:High-lights of the St.Gallen International Expert Consensus on the Primary Therapy ofEarly Breast Cancer 2011[J].Ann Oncol,2011,22 (8):1736-1747.
• [14] Denkert C,Minckwitz GV,Darb-Esfahani S,et al.Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer:a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol,2018,19(1):40-50.
• [15] Chen XS,Wu JY,Huang O,et al.Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy[J].Oncol Rep,2010,23(5):1213-1220.
• [16] 余韬,李岩.三阴性乳腺癌生存分析及预后影响因素[J].实用肿瘤杂志,2017,32(1):61-65.
• [17] 张同先,王亚红,张巍,等.Ki67作为 ER+和(或)PR+乳腺癌进一步分型指标的研究[J].实用医学杂志,2013,29(3):374-377.
• [18] Reyna C,Desnyder SM.Triple-negative breast cancer:who should receive neoadjuvant chemotherapy?[J].Surg Oncol Clin North Am,2018,27(1):141-153.
• [19] Goodman S,O′Connor A,Kandil D,et al.The ever-changing role of sentinel lymph node biopsy in the management of breast cancer[J].Arch Pathol Lab Med,2014,138(1):57-64.
• [20] 宋艳群,张斌,赵洪猛,等.阳性淋巴结比率对腋窝淋巴结受累乳腺癌患者总生存率的影响[J].实用肿瘤杂志,2011,26(1):33-36.
• [21] 黄欧,陈灿铭,胡震,等.腋淋巴结转移阳性乳腺癌NCT临床意义的探讨[J].中华肿瘤防治杂志,2009,16(24):1939-1941.
• [22] Jeruss JS,Mittendorf EA,Tucker SL,et al.Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy[J].Clin Oncol,2008,26(2):246-252.